Need help finding what you are looking for?
Contact Us
PUBLISHER: Inkwood Research | PRODUCT CODE: 1069200
PUBLISHER: Inkwood Research | PRODUCT CODE: 1069200
North America Drug Discovery Market Forecast 2022-2030
PUBLISHED:
PAGES: 162 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
KEY FINDINGS
The North America drug discovery market is estimated to register a CAGR of 6.14% during the forecast period, 2022-2030. The surging demands are accredited to the growing prioritization of several therapeutic areas like rare diseases and women's health.
REGIONAL INSIGHTS
The United States and Canada are assessed for the North America drug discovery market growth analysis. In Canada, the drug discovery and development market is comparatively small but is projecting gradual growth in terms of relevance and developments at multiple levels. For instance, Sunshine Biopharma, a pharmaceutical company in Canada, is engaged in the research, development, and commercialization of antiviral and oncology drugs.
Also, several Canadian-based biotechnology companies' and academic institutions' inventions and concepts have facilitated the development of essential drug delivery products that have improved the landscape of drug therapy in treating cancer and infectious diseases. Additionally, through partnerships, pharmaceutical companies' extensive R&D activities enable additional investments in small and medium-sized enterprises (SMEs) and venture funds. Besides, pharmaceutical sales in Canada doubled between 2001 and 2015, with hospitals and retail sales representing 12.5% and 87.5% of the total pharmaceutical sales, respectively. Such developments contribute to market growth.
COMPETITIVE INSIGHTS
Some of the leading companies in the market are: Icon Plc, Merck & Co Inc, Johnson & Johnson, IQVIA Holdings Inc, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Product Code: 13806
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. SCOPE OF STUDY
- 1.3. METHODOLOGY
- 1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
- 3.1. KEY DRIVERS
- 3.1.1. GROWING R&D FOR TACKLING SEVERAL DISEASES
- 3.1.2. TECHNOLOGICAL ADVANCEMENTS
- 3.2. KEY RESTRAINTS
- 3.2.1. EXTENSIVE TIME-CONSUMING PROCESS
- 3.2.2. HIGHLY REGULATED MARKET
- 3.2.3. PROJECT FEASIBILITY AND SUCCESS RATE
4. KEY ANALYTICS
- 4.1. IMPACT OF COVID-19 ON DRUG DISCOVERY MARKET
- 4.2. KEY MARKET TRENDS
- 4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
- 4.4. OPPORTUNITY MATRIX
- 4.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
- 4.5.1. DRUG DISCOVERY AND DEVELOPMENT
- 4.5.2. PRECLINICAL RESEARCH
- 4.5.3. CLINICAL RESEARCH
- 4.5.4. REGULATORY AUTHORITY REVIEW
- 4.5.5. POST MARKET SAFETY MONITORING
- 4.6. REGULATORY FRAMEWORK
5. MARKET BY DRUG TYPE
- 5.1. SMALL MOLECULE DRUG
- 5.2. BIOLOGIC DRUG
6. MARKET BY SERVICE
- 6.1. CHEMICAL SERVICES
- 6.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
- 6.3. BIOLOGICAL SERVICES
- 6.4. OTHER PHARMACEUTICAL SERVICES
7. MARKET BY END-USER
- 7.1. PHARMACEUTICAL COMPANIES
- 7.2. CONTRACT RESEARCH ORGANIZATIONS
- 7.3. RESEARCH INSTITUTES
- 7.4. OTHER END-USERS
8. MARKET BY TECHNOLOGY
- 8.1. HIGH THROUGHPUT SCREENING
- 8.2. SPECTROSCOPY
- 8.3. COMBINATORIAL CHEMISTRY
- 8.4. BIOCHIPS
- 8.5. PHARMACOGENOMICS AND PHARMACOGENETICS
- 8.6. BIOINFORMATICS
- 8.7. METABOLOMICS
- 8.8. NANOTECHNOLOGY
- 8.9. OTHER TECHNOLOGIES
9. GEOGRAPHICAL ANALYSIS
- 9.1. NORTH AMERICA
- 9.1.1. MARKET SIZE & ESTIMATES
- 9.1.2. KEY GROWTH ENABLERS
- 9.1.3. KEY CHALLENGES
- 9.1.4. KEY PLAYERS
- 9.1.5. COUNTRY ANALYSIS
- 9.1.5.1. UNITED STATES
- 9.1.5.2. CANADA
10. COMPETITIVE LANDSCAPE
- 10.1. KEY STRATEGIC DEVELOPMENTS
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 10.1.3. PARTNERSHIPS & AGREEMENTS
- 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
- 10.2. COMPANY PROFILES
- 10.2.1. AGILENT TECHNOLOGIES INC
- 10.2.2. ASTRAZENECA PLC
- 10.2.3. BAYER AG
- 10.2.4. CHARLES RIVER LABORATORIES INTERNATIONAL INC
- 10.2.5. ELI LILLY AND COMPANY
- 10.2.6. EVOTEC SE
- 10.2.7. GLAXOSMITHKLINE PLC
- 10.2.8. ICON PLC
- 10.2.9. IQVIA HOLDINGS INC
- 10.2.10. JOHNSON & JOHNSON
- 10.2.11. MERCK & CO INC
- 10.2.12. NOVARTIS AG
- 10.2.13. PFIZER INC
- 10.2.14. ROCHE AG
Product Code: 13806
LIST OF TABLES
- TABLE 1: MARKET SNAPSHOT - NORTH AMERICA DRUG DISCOVERY
- TABLE 2: REGULATORY FRAMEWORK
- TABLE 3: NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 4: NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 5: NORTH AMERICA DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 6: NORTH AMERICA DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 7: NORTH AMERICA DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 8: NORTH AMERICA DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 9: NORTH AMERICA DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 10: NORTH AMERICA DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 11: NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 12: NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 13: LEADING PLAYERS OPERATING IN NORTH AMERICA DRUG DISCOVERY MARKET
- TABLE 14: LIST OF MERGERS & ACQUISITIONS
- TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
- TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
- TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
- FIGURE 1: KEY MARKET TRENDS
- FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 3: OPPORTUNITY MATRIX
- FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
- FIGURE 5: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
- FIGURE 6: NORTH AMERICA DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
- FIGURE 7: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
- FIGURE 8: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
- FIGURE 9: NORTH AMERICA DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
- FIGURE 10: NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
- FIGURE 11: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
- FIGURE 12: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
- FIGURE 13: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
- FIGURE 14: NORTH AMERICA DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
- FIGURE 15: NORTH AMERICA DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
- FIGURE 16: NORTH AMERICA DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
- FIGURE 17: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
- FIGURE 18: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
- FIGURE 19: NORTH AMERICA DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
- FIGURE 20: NORTH AMERICA DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
- FIGURE 21: NORTH AMERICA DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
- FIGURE 22: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
- FIGURE 23: NORTH AMERICA DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
- FIGURE 24: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
- FIGURE 25: NORTH AMERICA DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
- FIGURE 26: NORTH AMERICA DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
- FIGURE 27: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
- FIGURE 28: NORTH AMERICA DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
- FIGURE 29: UNITED STATES DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 30: CANADA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.